Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16.
Schoentgen N, Marolleau J, Delage F, Coquet JB, Fourcade A, Callerot P, Serey-Eiffel S, Malhaire JP, Pradier O, Schick U, Fournier G, Valeri A. Schoentgen N, et al. Among authors: fourcade a. J Contemp Brachytherapy. 2019 Jun;11(3):195-200. doi: 10.5114/jcb.2019.85793. Epub 2019 Jun 28. J Contemp Brachytherapy. 2019. PMID: 31435425 Free PMC article.
Magnetic Resonance Imaging-based T-staging to Predict Biochemical Recurrence after Radical Prostatectomy: A Step Towards the iTNM Classification.
Baboudjian M, Gondran-Tellier B, Touzani A, Martini A, Diamand R, Roche JB, Lacetera V, Beauval JB, Roumeguère T, Simone G, Benamran D, Fourcade A, Fiard G, van den Bergh RCN, Peltier A, Ploussard G. Baboudjian M, et al. Among authors: fourcade a. Eur Urol Oncol. 2023 Aug;6(4):406-413. doi: 10.1016/j.euo.2022.09.005. Epub 2022 Oct 21. Eur Urol Oncol. 2023. PMID: 36280445
Oncological outcomes of radical prostatectomy in very high-risk patients according to STAMPEDE criteria: does local treatment alone still have a place in the era of intensified systemic therapies?
Baboudjian M, Touzani A, Martini A, Diamand R, Roche JB, Lacetera V, Beauval JB, Gondran-Tellier B, Roumeguère T, Simone G, Windisch O, Benamran D, Fourcade A, Fiard G, VAN DEN Bergh RC, Peltier A, Ploussard G. Baboudjian M, et al. Among authors: fourcade a. Minerva Urol Nephrol. 2023 Feb;75(1):124-126. doi: 10.23736/S2724-6051.22.05121-7. Epub 2022 Oct 25. Minerva Urol Nephrol. 2023. PMID: 36282548 Free article. No abstract available.
Évaluation du « Quadrella » a 2ans : nouvel indice de performance oncologique et fonctionnelle spécifique de la curiethérapie prostatique.
Coquet J, Delage F, Perrouin-Verbe M, Malhaire J, Schoentgen N, Fourcade A, Rousseau B, Thoulouzan M, Callerot P, Fournier G, Valeri A. Coquet J, et al. Among authors: fourcade a. Prog Urol. 2015 Nov;25(13):836-7. doi: 10.1016/j.purol.2015.08.242. Prog Urol. 2015. PMID: 26544435 French. No abstract available.
Evaluation of the "Quadrella" at 3 years: New index to assess functional and oncological performance specific to prostate brachytherapy.
Coquet JB, Delage F, Fourcade A, Callerot P, Goasduff G, Boussion N, Rousseau B, Serey-Eiffel S, Malhaire JP, Pradier O, Schick U, Fournier G, Valeri A. Coquet JB, et al. Among authors: fourcade a. Brachytherapy. 2018 Sep-Oct;17(5):782-787. doi: 10.1016/j.brachy.2018.05.007. Epub 2018 Jun 21. Brachytherapy. 2018. PMID: 29936129
Impact of Multiparametric MRI and PSA Density on the Initial Indication or the Maintaining in Active Surveillance During Follow-Up in low-Risk Prostate Cancer.
Saout K, Zambon A, Nguyen TA, Lucas C, Payrard-Starck C, Segalen T, Tissot V, Doucet L, Marolleau J, Deruelle C, Joulin V, Fourcade A, Fournier G, Valeri A. Saout K, et al. Among authors: fourcade a. Clin Genitourin Cancer. 2022 Jun;20(3):e244-e252. doi: 10.1016/j.clgc.2022.01.015. Epub 2022 Jan 31. Clin Genitourin Cancer. 2022. PMID: 35216924
96 results